Transcode Therapeutics names Interim CFO John A. Tattory in initial beneficial ownership filing
RNAZ•Initial Form 3 filing
- Transcode Therapeutics Interim CFO John A. Tattory filed an initial Form 3 beneficial ownership statement dated Sept. 10, 2026.
Related News
First Breach CRO Charles Kenneth Leith acquires 50,000 common shares valued at $45,330
FBDT•
Woodward Plans To Transition Its Santa Clarita, California, Aerospace Controls Production To Spartanburg, South Carolina
WWD•
Marcus & Millichap brokers USD 6.2 million sale of 24-unit Los Angeles multifamily property
MMI•
